1-3 of 3
Yingsi Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Clinical Trials & Observations
Harriet S. Walter, Sandrine Jayne, Simon A. Rule, Guillaume Cartron, Franck Morschhauser, Salvador Macip, Lionel Karlin, Ceri Jones, Charles Herbaux, Philippe Quittet, Nimish Shah, Claire V. Hutchinson, Christopher Fegan, Yingsi Yang, Siddhartha Mitra, Gilles Salles, Martin J. S. Dyer
Journal: Blood
Blood (2017) 129 (20): 2808–2810.
https://doi.org/10.1182/blood-2017-02-765115
Published: 2017
Includes: Supplemental data
Journal Articles

Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

Harriet S. Walter, Sandrine Jayne, Simon A. Rule, MD, Guillaume Cartron, MD PhD, Franck Morschhauser, Christopher Fegan, Yingsi Yang, Siddhartha Mitra, Martin J.S. Dyer, Gilles A. Salles
Journal: Blood
Blood (2016) 128 (22): 3233.
https://doi.org/10.1182/blood.V128.22.3233.3233
Published: 2016
Journal Articles

Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies

Gilles A. Salles, Franck Morschhauser, Bruce Cheson, MD, Simon A. Rule, MD, Christopher Fegan, Cartron Guillaume, Cara Nelson, Yingsi Yang, Siddhartha Mitra, Alexander Starodub, Martin J.S. Dyer
Journal: Blood
Blood (2016) 128 (22): 2961.
https://doi.org/10.1182/blood.V128.22.2961.2961
Published: 2016